Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of Syk Inhibitor Entospletinib (GS-9973) in Combination With Obinutuzumab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and B-Cell Malignancies

NCT03010358 is registered in ClinicalTrials.gov with Alexey Danilov, MD as lead sponsor.

NCT NCT03010358
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03010358 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of Syk Inhibitor Entospletinib (GS-9973) in Combination With Obinutuzumab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and B-Cell Malignancies
Lead sponsor
Alexey Danilov, MD
Phase
Phase 1/2
Overall status
Completed
Start date
July 17, 2017
Completion date
April 29, 2021
Enrollment
24 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anemia, b-cell prolymphocytic leukemia, grade 1 follicular lymphoma, grade 2 follicular lymphoma, grade 3a follicular lymphoma, hairy cell leukemia, lymphoplasmacytic lymphoma, mantle cell lymphoma, marginal zone lymphoma, recurrent chronic lymphocytic leukemia, recurrent small lymphocytic lymphoma, refractory chronic lymphocytic leukemia, refractory small lymphocytic lymphoma, richter syndrome